REVIVA PHARMACEUTICALS

1,1400

27-ноября-24 16:45:00

15 мин. задержка

Акции

+0,0200

+1,79%

Сегодняшний диапазон

1,1100 - 1,2200

ISIN

N/A

Источник

NASDAQ

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 ноя 2024 17:25:00 Источник Nasdaq GlobeNewswire
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

12 ноя 2024 08:00:02 Источник Nasdaq GlobeNewswire
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

06 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Participate in the UBS Global Healthcare Conference

31 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

08 окт 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

02 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

26 сен 2024 08:30:00 Источник Nasdaq GlobeNewswire
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

09 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

27 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

21 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

06 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

09 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

29 май 2024 16:45:48 Источник Nasdaq GlobeNewswire
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

28 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Participate in the BIO International Convention

21 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

15 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

14 май 2024 08:00:00 Источник Nasdaq GlobeNewswire
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

13 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.